ALLHAT: A saga of missed opportunities

Journal of Human Hypertension

Volumn 17, Issue 6, 2003, Pages 373-377

  McInnes, G T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; LISINOPRIL; RESERPINE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG COST; DRUG SAFETY; EDEMA; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; METABOLIC DISORDER; NOTE; OUTCOMES RESEARCH; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS;

EID: 0038042045     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001564     Document Type: Note

References (32)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
2. Kaplan NM. How bad are diuretic-induced hypokalemia and hypercholesterolemia? Arch Intern Med 1989; 149: 2649.
3. Poole-Wilson PA. Hypokalaemia induced by thiazide diuretics in the treatment of hypertension: A cause for concern, not nihilism. Postgrad Med J 1983; 59 (Suppl 3): 137-139.
4. Poulter N, Sever P, Thom S. Antihypertensive and adverse biochemical effects of bendrofluazide. BMJ 1990; 300: 1465.
5. Robertson JIS. Hypertension and coronary risk: Possible adverse effects of antihypertensive drugs. Am Heart J 1987; 114: S1051-S1054.
6. Weinberger MH. Diuretics and their side-effects. Dilemma in the treatment of hypertension. Hypertension 1988; 11 (Suppl II): II-16-II-20.
7. Yusuf S et al. Beta-blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
8. Collins R et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
9. Psaty BM et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
10. Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354: 1751-1756.
11. Hansson L et al., for the Captopril Prevention Project (CAPP) study group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
12. Brown MJ et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-377.
13. Hansson L et al., for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356: 359-365.
14. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-1964.
15. Pahor M et al. Health outcomes associated with calcium antagonists compared with the first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000; 352: 1949-1954.
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
17. Hansson L et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1988; 351: 1755-1762.
18. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305-1315.
19. Tuomilehto J et al., for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
20. Ramsay L et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
21. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2461.
22. Cushman WS et al. Regional and racial difference in response to antihypertensive medication use in a randomised controlled trial of men with hypertension in the United States. Arch Intern Med 2000; 160: 825-831.
23. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am 1997; 26: 125-144.
24. Saunders E et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713.
25. Cushman WC et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-405.
26. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5: 178-187.
27. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351-1357.
28. Cutler JA. Calcium channel blockers for hypertension - Uncertainty continues. N Engl J Med 1998; 338: 679-681.
29. Furberg CD, Psaty BM, Meyer JV Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events on hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
31. Davis BR et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137; 313-320.
32. McInness GT, Yeo WW, Ramsay LE, Moser M. Cardiotoxicity of diuretics: Much speculation-little substance. J Hypertens 1992; 10: 317-335.